US Patent Issued to Celgene on Aug. 25 for "Modulators of CAMKK2 as ligand directed degraders" (California, Massachusetts Inventors)

ALEXANDRIA, Va., Aug. 25 -- United States Patent no. 12,715,869, issued on Aug. 25, was assigned to Celgene Corp. (Princeton, N.J.).

"Modulators of CAMKK2 as ligand directed degraders" was invented by Laura Akullian D'Agostino (Sudbury, Mass.), Brandon Whitefield (San Diego) and Young Chen (San Marcos, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are compounds of formula (I) and compositions thereof for modulating CAMKK2. In some embodiments, the compounds and compositions are provided for treatment of cancer and/or obesity."

The patent was filed on Oct. 7, 2022, under Application No. 18/694,691.

*For further information, including images, charts and tables, please visit: http://pa...